News


Sygnature Discovery expands DMPK team with appointment of Dr. Edward Browne

Sygnature announces the expansion of its DMPK team with the appointment of Dr Ed Browne as Associate Director of DMPK. Ed is an experienced drug discovery scientist who brings a thorough understanding of developing and prosecuting a lead optimisation strategy, having worked at GSK, Singapore for the last ten years as head of the Drug […]

Sygnature Discovery and Viramatix announce anti-viral drug discovery strategic alliance

Nottingham, UK and Kuala Lumpur, Malaysia; 5th October 2016 – Sygnature Discovery Limited, the UK’s largest independent provider of integrated drug discovery resources and expertise, and Viramatix Sdn. Bhd., a biopharmaceutical company involved in the discovery of peptide based anti-viral therapeutics, today announced their ongoing collaboration on innovative anti-influenza therapeutics. Influenza virus infection remains a […]

The Corona sculpture starts to take shape on the new ‘Discovery’ building

Sygnature Discovery today saw the start of the Brise Soleil installation on the front of the new £30m ‘Discovery’ building. which will reduce the risk of the building overheating. The sculpture known as Corona forms a curtain of metal tubes 17 metres high across the front of the building which are linked to NASA satellites […]

Sygnature are exhibiting at ELRIG’s Drug Discovery 2016 event at the ACC, Liverpool. Stand G1

Drug Discovery 2016 will bring together 1000 delegates and 50 world-class speakers from academia and industry, each representing critical areas in drug discovery. Scientific Sessions: Innovations in Chemistry Oncology & Immunology Innovations in Predictive & Translational Models Assay Development, Screening & Emerging Technologies Coming Closer to the Patient – Cells & Genes in Therapy & […]

Sygnature Discovery’s drug discovery capabilities enhanced by acquisition of BMG LABTECH PHERAstar® FSX

July 20th 2016 – Nottingham, UK – Sygnature Discovery Limited, the UK’s largest independent provider of integrated drug discovery resource and expertise, today announced the addition of the BMG LABTECH PHERAstar® FSX into its portfolio of advanced in vitro screening capabilities. In order to maximise assay performance during drug discovery projects, Sygnature is striving to […]

Page 2 of 1012345...10...Last »
Copyright © 2017 Sygnature Discovery

Website built by AtomicMedia - Design by Freestyle.